Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease (Q24186304)

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Antioxidant treatment with N-acetylcysteine and vitamin C in patients with chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immuno

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

A measure of quality of life for clinical trials in chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Tiotropium versus placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

N‐isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

St. George's Respiratory Questionnaire: MCID

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001287.PUB5

7 January 2021

10.1002/14651858.CD001287.PUB5

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

26222376

1 reference

Consolidated OpenCitations Corpus – April 2017